PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	SECURITY AGREEMENT	

CONVEYING PARTY DATA

Name	Execution Date
BAXA Corporation	06/23/2006

RECEIVING PARTY DATA

Name:	Goldman, Sachs & Co.
Street Address:	85 Broad Street
City:	New York
State/Country:	NEW YORK
Postal Code:	10004

PROPERTY NUMBERS Total: 26

Property Type	Number
Patent Number:	6813868
Patent Number:	6976349
Patent Number:	6915619
Patent Number:	6957522
Application Number:	90007816
Application Number:	90007817
Application Number:	90007815
Patent Number:	5084021
Patent Number:	4976590
Patent Number:	6953450
Patent Number:	6338200
Patent Number:	5024347
Patent Number:	4863429
Patent Number:	4317448
Patent Number:	4303071
	DATENT

PATENT REEL: 018535 FRAME: 0339

500182065

Patent Number:	5135491
Patent Number:	4755172
Application Number:	10864610
Application Number:	10226183
Application Number:	11173506
Application Number:	10226599
Application Number:	11036644
Application Number:	11125774
Application Number:	11242618
Application Number:	60742114
PCT Number:	US0600137

CORRESPONDENCE DATA

Fax Number: (703)773-5200

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 703-773-4002

Email: margaret.filipowicz@dlapiper.com

Correspondent Name: Lisa K. Norton Address Line 1: P.O. Box 9271

Address Line 4: Reston, VIRGINIA 20195

ATTORNEY DOCKET NUMBER: 361801-2

NAME OF SUBMITTER: Lisa K. Norton

Total Attachments: 17

source=BAXAGoldmanSecurityAgreement#page1.tif source=BAXAGoldmanSecurityAgreement#page2.tif source=BAXAGoldmanSecurityAgreement#page3.tif source=BAXAGoldmanSecurityAgreement#page4.tif source=BAXAGoldmanSecurityAgreement#page5.tif source=BAXAGoldmanSecurityAgreement#page6.tif source=BAXAGoldmanSecurityAgreement#page7.tif source=BAXAGoldmanSecurityAgreement#page8.tif source=BAXAGoldmanSecurityAgreement#page9.tif source=BAXAGoldmanSecurityAgreement#page10.tif source=BAXAGoldmanSecurityAgreement#page11.tif source=BAXAGoldmanSecurityAgreement#page12.tif source=BAXAGoldmanSecurityAgreement#page13.tif source=BAXAGoldmanSecurityAgreement#page14.tif source=BAXAGoldmanSecurityAgreement#page15.tif source=BAXAGoldmanSecurityAgreement#page16.tif source=BAXAGoldmanSecurityAgreement#page17.tif

SECOND LIEN PATENT, TRADEMARK AND LICENSE SECURITY AGREEMENT

THIS SECOND LIEN PATENT, TRADEMARK AND LICENSE SECURITY AGREEMENT (this "Agreement") is made and entered into as of the 23rd day of June, 2006, between BAXA CORPORATION, a Colorado corporation ("Company"), and GOLDMAN, SACHS & CO. ("Secured Party").

WITNESSETH:

WHEREAS, Company, Secured Party and certain other parties are herewith entering into the Series A Convertible Preferred Stock Purchase Agreement dated as of the date hereof (as the same may from time to time be amended, modified, extended, renewed and restated, the "Purchase Agreement"); and

WHEREAS, as a condition precedent to Secured Party entering into the Purchase Agreement, Secured Party has required that Company execute and deliver this Agreement to Secured Party; and

WHEREAS, in order to induce Secured Party to enter into the Purchase Agreement, Company has agreed to execute and deliver this Agreement to Secured Party;

WHEREAS, this Agreement is being executed in connection with and in addition to the Second Lien Security Agreement dated as of the date hereof between Company and Secured Party (as the same may from time to time be amended, modified, extended, renewed and restated, the "Second Lien Security Agreement") pursuant to which Company has granted to Secured Party a security interest in and lien on the substantially all business assets of Company, including, without limitation, all accounts, inventory, general intangibles, goods, machinery, equipment, books, records, goodwill, patents, patent applications, trademarks and trademark applications now owned or hereafter acquired by Company and all proceeds thereof; all capitalized terms used and not otherwise defined in this Agreement shall have the respective meanings ascribed to them in the Second Lien Security Agreement;

NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Company hereby covenants and agrees with Secured Party as follows:

- 1. Grant of Security Interest. For value received, Company hereby grants Secured Party a security interest in and lien on all of Company's right, title and interest in, to and under the following described property, whether now owned and existing or hereafter created, acquired or arising (collectively, the "Collateral"):
 - (a) all patents and patent applications, and the inventions and improvements described and claimed therein, including, without limitation, each patent and patent application listed on Schedules A and B, respectively, attached hereto and incorporated herein by reference (as the same may be amended pursuant hereto from time to time) and (i) the reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof, (ii) all income, damages and payments now and/or hereafter due or payable under or with respect thereto, including, without limitation, license royalties, damages and payments for past or future infringements thereof, (iii) the right to sue for past, present and future infringements thereof and (iv) all rights corresponding thereto throughout the world (all of the foregoing patents and patent applications together with the items described in clauses (i) through (iv) of this subsection (a) are hereinafter collectively referred to herein as the "Patents");

- (b) all trademarks, service marks, trademark or service mark registrations, trade names, trade styles, trademark or service mark applications and brand names, including, without limitation, common law rights and each mark and application listed on Schedules C and D, respectively, attached hereto and incorporated herein by reference; and (i) renewals or extensions thereof, (ii) all income, damages and payments now and/or hereafter due or payable with respect thereto, including, without limitation, license royalties, damages and payments for past or future infringements thereof, (iii) the right to sue for past, present and future infringements thereof and (iv) all rights corresponding thereto throughout the world (all of the foregoing trademarks, trade names, service marks and applications and registrations thereof together with the items described in clauses (i) through (iv) of this subsection (b) are hereinafter collectively referred to herein as the "Trademarks");
- (c) the license(s) listed on <u>Schedule E</u> attached hereto and incorporated herein by reference and all other license agreements (to the extent such license agreements may be assigned without violating the terms of any such license agreement) with respect to any of the Patents or the Trademarks or any other patent, trademark, service mark or any application or registration thereof or any other trade name or trade style between Company and any other Person, whether Company is licensor or licensee (all of the forgoing license agreements and Company's rights thereunder are hereinafter collectively referred to as the "Licenses");
- (d) the goodwill of Company's business connected with and symbolized by the Trademarks; and
- (e) all proceeds, including, without limitation, proceeds that constitute property of the types described in (a), (b), (c) and (d) above and any rents and profits of any of the foregoing items, whether cash or noncash, immediate or remote, and insurance proceeds, and all products of (a), (b), (c) and (d) above, and any indemnities, warranties and guaranties payable by reason of loss or damage to or otherwise with respect to any of the foregoing items;

to secure the payment when due by Company to Secured Party of (a) the Series A Redemption Price (as defined in the Second Amended and Restated Articles of Incorporation of Company as filed with the Colorado Secretary of State on the date hereof, as amended, restated, supplemented or otherwise modified from time to time (the "Articles")), (b) the payment obligations in respect of the Series A Convertible Preferred Stock issued by Company pursuant to the Purchase Agreement (the "Series A Convertible Preferred Stock") and accrued and unpaid dividends accruing thereon and (c) all fees, costs and expenses, now and from time to time hereafter owing, due or payable to Secured Party (hereinafter referred to as the "Secured Obligations"). The parties acknowledge that the foregoing is a grant of security interest and lien, and not an assignment or other transfer.

- 2. <u>Further Assurances</u>. From and after the date of this Agreement, upon the request of Secured Party, Company shall execute and deliver such instruments, documents and other writings as may be reasonably necessary or desirable to confirm and carry out and to effectuate fully the intent and purposes of this Agreement.
- 3. Additional Patents, Trademarks and Licenses. If Company (a) becomes aware of any existing Patents, Trademarks or Licenses of which Company has not previously informed Secured Party, (b) obtains rights to any new patentable inventions, Patents, Trademarks and/or Licenses or (c) becomes entitled to the benefit of any Patents, Trademarks and/or Licenses which benefit is not in existence on the date of this Agreement, the provisions of this Agreement shall automatically apply thereto.
 - 4. <u>Modification by Secured Party</u>. Company authorizes Secured Party to modify this

Agreement by amending <u>Schedules A, B, C, D</u> and/or <u>E</u> to include any future patents and patent applications, any future trademarks, service marks, trademark or service mark registrations or applications thereof, trade names, and trademark or service applications, and any future licenses, covered by Paragraphs 1 and 3 hereof, without the signature of Company if permitted by applicable law.

- 5. <u>Use of Patents, Trademarks and Licenses</u>. Company may use the Patents and Trademarks and exercise its rights under the Licenses in any lawful manner not inconsistent with this Agreement and otherwise consistent with commercially reasonable practices.
- Default; Remedies. Following Termination of all First Lien Obligations, if any Event of Default (as defined under the Second Lien Security Agreement) shall have occurred and be continuing, Secured Party shall have, in addition to all other rights and remedies given it by this Agreement, those allowed by law and the rights and remedies of a secured party under the UCC as enacted in any jurisdiction in which any of the Patents, Trademarks and/or Licenses may be located and, without limiting the generality of the foregoing, Secured Party may immediately, without demand of performance and without other notice (except as set forth next below) or demand whatsoever to Company, all of which are hereby expressly waived, and without advertisement, sell at public or private sale or otherwise realize upon, all or from time to time any of the Patents, Trademarks (together with the goodwill of Company associated therewith) and/or Licenses, or any interest that Company may have therein, and after deducting from the proceeds of sale or other disposition of the Patents, Trademarks or Licenses all expenses (including, without limitation, all expenses for brokers' fees and legal services), shall apply the residue of such proceeds toward the payment of the Secured Obligations in the order and manner as Secured Party may elect. Notice of any sale or other disposition of any of the Patents, Trademarks and/or Licenses shall be given to Company at least ten (10) business days before the time of any intended public or private sale or other disposition of such Patents, Trademarks and/or Licenses is to be made, which Company hereby agrees shall be reasonable notice of such sale or other disposition. At any such sale or other disposition, Secured Party or any holder of any of the Secured Obligations may, to the extent permissible under applicable law, purchase the whole or any part of the Patents, Trademarks and/or Licenses sold, free from any right of redemption on the part of Company, which right is hereby waived and released. Company agrees that, following Termination of all First Lien Obligations, if any Event of Default has occurred and is continuing, the use by Secured Party of the Patents, Trademarks and Licenses shall be worldwide, and without any liability for royalties or other related charges from Secured Party to Company; provided that any such use shall inure to the benefit of Company and be consistent with Company's past practices. All of Secured Party's rights and remedies with respect to the Patents, Trademarks and Licenses, whether established hereby, by the Second Lien Security Agreement or by any other agreement or by law shall be cumulative and may be exercised singularly or concurrently. Notwithstanding anything contained herein, no Trademark shall be sold or otherwise disposed of without the goodwill of Company's business connected with and symbolized by that Trademark; and no so-called "Intent-to-Use" trademark application shall be sold or otherwise disposed of apart from the business of Company, or portion thereof, to which such application pertains, as required by 15 U.S.C. §1060. The phrase "Termination of all First Lien Obligations" shall have the meaning set forth in the Subordination Agreement, dated as of the date hereof, among Secured Party, Company and U.S. Bank National Association (as the same may from time to time be amended, modified, extended, renewed or restated, the "Subordination Agreement").
- 7. Preservation of Patents, Trademarks and Licenses. Following Termination of all First Lien Obligations, Company shall have the duty to Secured Party (a) to prosecute diligently any patent, trademark or service mark applications pending as of the date hereof or hereafter except those applications which Company has determined in its good business judgment should not be prosecuted, (b) to make application on unpatented but patentable inventions and on trademarks and service marks, as commercially reasonable, provided Company has determined in its good business judgment should be applied for, and (c) to preserve and maintain all rights in the Patents, Trademarks and Licenses, as

commercially reasonable. Any expenses incurred in connection with Company's obligations under this Section 8 shall be borne by Company.

- 8. <u>No Waiver</u>. No course of dealing between Company and Secured Party, nor any failure to exercise, nor any delay in exercising, on the part of Secured Party, any right, power or privilege under this Agreement shall operate as a waiver thereof; nor shall any single or partial exercise of any right, power or privilege under this Agreement preclude any other or further exercise thereof or the exercise of any other right, power or privilege.
- 9. <u>Severability</u>. The provisions of this Agreement are severable, and if any clause or provision shall be held invalid and unenforceable in whole or in part in any jurisdiction, then such invalidity or unenforceability shall affect only such clause or provision, or part thereof, in such jurisdiction, and shall not in any manner affect such clause or provision in any other jurisdiction, or any other clause or provision of this Agreement in any jurisdiction.
- 10. <u>Amendments</u>. This Agreement is subject to amendment or modification only by a writing signed by Company and Secured Party, except as provided in Paragraph 4 above.
- Successors and Assigns: Duration of Security Interest. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. Secured Party may not assign, transfer or delegate any of its rights, obligations or duties under this Agreement except to an Affiliate (as defined in the Purchase Agreement) thereof to whom Secured Party has transferred all of its shares of Series A Convertible Preferred Stock of Company (a "Permitted Transferee"). Company may not assign, transfer or delegate any of its rights, obligations or duties under this Agreement. This Agreement shall continue in full force and effect and the security interest and lien granted by this Agreement and all of the representations, warranties, covenants and agreements of Company and Secured Party under this Agreement and all of the terms, conditions and provisions of this Agreement relating thereto shall continue to be fully operative until such time as Secured Party or its Permitted Transferee no longer owns any shares of Series A Convertible Preferred Stock of Company. At such time Secured Party shall execute and deliver to Company all instruments as may be necessary or proper to extinguish Secured Party's security interests created hereby. THIS INSTRUMENT AND THE RIGHTS AND OBLIGATIONS EVIDENCED HEREBY ARE SUBORDINATE IN THE MANNER AND TO THE EXTENT SET FORTH IN THE SUBORDINATION AGREEMENT TO THE INDEBTEDNESS (INCLUDING INTEREST), AND THE LIENS AND SECURITY INTERESTS SECURING INDEBTEDNESS OWED BY COMPANY AND CERTAIN AFFILIATES TO THE FIRST LIEN LENDERS (AS DEFINED IN THE SUBORDINATION AGREEMENT) AS MORE PARTICULARLY DESCRIBED IN THE SUBORDINATION AGREEMENT; AND EACH HOLDER OF THIS INSTRUMENT, BY ITS ACCEPTANCE HEREOF, IRREVOCABLY AGREES TO BE BOUND BY THE PROVISIONS OF THE SUBORDINATION AGREEMENT.
- 12. Governing Law; Conflict. The validity and interpretation of this Agreement and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the substantive laws of the State of Colorado (without reference to conflict of law principles). In the event of any conflict between any term, covenant or condition of this Agreement and any term, covenant or condition of the Subordination Agreement, the provisions of the Subordination Agreement shall control. In the event of any conflict between any term, covenant or condition of this Agreement and any term, covenant or condition of the Purchase Agreement, the Investor Rights Agreement (as defined in the Purchase Agreement) or the Articles, the provisions of the Purchase Agreement, the Investor Rights Agreement, the Stockholders Agreement or the Articles, as the case may be, shall control. Notwithstanding anything to the contrary in this Agreement, whenever Secured Party has the right to act in its discretion it shall act reasonably and in

good faith and Secured Party shall not exercise any of its rights or remedies under this Agreement in a manner that would result in the payment or satisfaction of any Secured Obligation that would not be permitted to be paid or satisfied as determined by the board of directors of Company under applicable law.

- 13. <u>Notices.</u> Except as otherwise specified in this Agreement, any notice, request, demand, consent or other communication under this Agreement shall be in writing and delivered in accordance with Section 6.03 of the Purchase Agreement.
- 14. <u>Headings: Counterparts.</u> Section and subsection headings in this Agreement are included herein for convenience of reference only and shall not constitute a part of this Agreement for any other purpose. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument, and any of the parties hereto may execute this Agreement by signing any such counterpart.

Signature page follows.

-5 -

IN WITNESS WHEREOF, Company and Secured Party have executed this Second Lien Patent. Trademark and License Security Agreement as of the date first written above.

	RPORATION (Company) /	····/ <	
n 2/1	segan.	15/	Lui	
Name: Gi	$\mathcal{P} = \mathcal{Q}$		-VV-	77
Title: Ch	airnavan	DAMMIN	e fige en la re- talignia a re-	1 1 1 2
1 La Train	salah Pada Satan	est, the same square as a second	1 - 50 30 - 23 - 22 -	

GOLDMAN, SACHS & CO. (Secured Party)

		Maria de la composição de	
lame!			 in the second
itle:	minimum and the second second		

IN WITNESS WHEREOF, Company and Secured Party have executed this Second Lien Patent, Trademark and License Security Agreement as of the date first written above.

3ÿ	
lamo:	
Fitle:	
FOLDM	AN, SACHS & CO. (Secured Party)
GOLDM By //	AN, SACHS, & CO. (Secured Party)
,	AN, SACHS & CO. (Secured Party) Alph Uramon

SIGNATURE PAGE TO SECOND LIEN PATENT, TRADEMARK AND LICENSE SECURITY AGREEMENT

CERTIFICATE OF ACKNOWLEDGMENT

STATE OF COLORADO) COUNTY OF)	SS.
The foregoing instrument by	was acknowledged before me the day of, 2006 President of Baxa Corporation, a Colorado corporation.
(Seal)	NI-town Dull's
My Commission Expires:	Notary Public
STATE OF) SS OF)	.
The foregoing instrument w	as acknowledged before me the day of, 2006 of Goldman, Sachs & Co.
(Seal)	
***************************************	Notary Public
My Commission Expires:	

-7-

SCHEDULE A

United States Patents

UNITED 50012-00027 DIVISIONAL July 30, 10/630,059 December 6,976,349 ISSUED 50012-00030 CON December 10/727,142 July 12, 6,915,619 ISSUED 5TATES 3, 2003 2005	COUNTRY	PEFERENCE P	TYPE	DATE FILED	SERIAL#	DATE ISSUED	PATENT	STATUS
STATES 2001 9, 2004 9, 2004 9, 2004 9, 2004 1850et	003.01.02	.01-PTA UTL CO	N HANDLING S	SYRINGES, M	ETHOD FOR			. •
STATES 2003 20,2005 20,2004 20,2005 20,2004 20,2005 20,2004 20,2005		50012-00004	FCA		09/928,007		6,813,868	ISSUED
UNITED 50012-00047 RE November 90/007,816 November 5,813,868 ISSUED STATES EXAMINED 22, 2005 9,2004		50012-00027	DIVISIONAL		10/630,059		6,976,349	ISSUED
STATES 3, 2003 25, 2005 2		50012-00030	CON		10/727,142	- ,	6,915,619	ISSUED
### STATES		50012-00031	CON		10/727,097		6,957,522	ISSUED
TATES EXAMINED 22, 2005 2005 UNITED 50012-00049 RE- November 90/007,815 October 6,957,522 ISSUED 5TATES EXAMINED 22, 2005 25, 2005 25, 2005 O09-PTA UTL PATIENT CONTROLLED INFUSION APPARATUS AND METHOD UNITED 50012- NEW November 07/608,283 January 28, 5,084,021 ISSUED 5TATES 00009 2, 1990 1992 O12-PTR UTL FLUID CONDUIT-RESPONSIVELY ADJUSTABLE PUMP ARRANGEMENT AND PUMP/CONDUIT ARRANGEMENT AND METHOD, AND FLUID CONDUITS THEREFOR UNITED 50012- NEW June 8, 07/203,926 December 4,976,590 ISSUED 5TATES 00012 1988 11, 1990 O22-PTA UTL ADMINISTRATION OF IV LIQUID MEDICATION AND IV FLUSH SOLUTIONS, APPARATUS AND METHOD FOR		50012-00047			90/007,816		6,813,868	ISSUED
STATES EXAMINED 22, 2005 25, 2005 25, 2005 009-PTA UTL PATIENT CONTROLLED INFUSION APPARATUS AND METHOD UNITED 50012- NEW November 07/608,283 January 28, 5,084,021 ISSUED 1992 012-PTR UTL FLUID CONDUIT-RESPONSIVELY ADJUSTABLE PUMP ARRANGEMENT AND PUMP/CONDUIT ARRANGEMENT AND METHOD, AND FLUID CONDUITS THEREFOR UNITED 50012- NEW June 8, 07/203,926 December 4,976,590 ISSUED 1988 11, 1990 022-PTA UTL ADMINISTRATION OF IV LIQUID MEDICATION AND IV FLUSH SOLUTIONS, APPARATUS AND METHOD FOR UNITED 50012- NEW August 22, 10/225,886 October 6,953,450 ISSUED 10012- NEW August 22, 10/225,886 October 6,953,450 ISSUED 10012- NEW August 22, 10/225,886 October 6,953,450 ISSUED 10012- NEW August 22, 10/225,886 October 6,953,450 ISSUED		50012-00048			90/007,817		6,915,619	ISSUED
UNITED 50012- NEW November 07/608,283 January 28, 5,084,021 ISSUED 012-PTR UTL FLUID CONDUIT-RESPONSIVELY ADJUSTABLE PUMP ARRANGEMENT AND PUMP/CONDUIT ARRANGEMENT AND METHOD, AND FLUID CONDUITS THEREFOR UNITED 50012- NEW June 8, 07/203,926 December 4,976,590 ISSUED 1988 11, 1990 022-PTA UTL ADMINISTRATION OF IV LIQUID MEDICATION AND IV FLUSH SOLUTIONS, APPARATUS AND METHOD FOR UNITED 50012- NEW August 22, 10/225,886 October 6,953,450 ISSUED STATES 00012- NEW August 22, 10/225,886 October 6,953,450 ISSUED		50012-00049			90/007,815		6,957,522	ISSUED
STATES 00009 2, 1990 1992 012-PTR UTL FLUID CONDUIT-RESPONSIVELY ADJUSTABLE PUMP ARRANGEMENT AND PUMP/CONDUIT ARRANGEMENT AND METHOD, AND FLUID CONDUITS THEREFOR UNITED 50012- NEW June 8, 07/203,926 December 4,976,590 ISSUED 1988 11, 1990 022-PTA UTL ADMINISTRATION OF IV LIQUID MEDICATION AND IV FLUSH SOLUTIONS, APPARATUS AND METHOD FOR UNITED 50012- NEW August 22, 10/225,886 October 6,953,450 ISSUED	009-PTA U	TL PATIENT CO	NTROLLED IN	FUSION APP	ARATUS AND	METHOD		
UNITED 50012- NEW June 8, 07/203,926 December 4,976,590 ISSUED 1988 11, 1990 022-PTA UTL ADMINISTRATION OF IV LIQUID MEDICATION AND IV FLUSH SOLUTIONS, APPARATUS AND METHOD FOR UNITED 50012- NEW August 22, 10/225,886 October 6,953,450 ISSUED			NEW		07/608,283		5,084,021	ISSUED
STATES 00012 1988 DECEMBER 4,976,390 ISSUED 022-PTA UTL ADMINISTRATION OF IV LIQUID MEDICATION AND IV FLUSH SOLUTIONS, APPARATUS AND METHOD FOR UNITED 50012- NEW August 22, 10/225,886 October 6,953,450 ISSUED	012-PTR UT ARRANGE	IL FLUID CONDI MENT AND MET	UIT-RESPONSI HOD, AND FLI	VELY ADJU: UID CONDUI	STABLE PUMP IS THEREFOR	ARRANGEMENT A	ND PUMP/C	ONDUIT
UNITED 50012- NEW August 22, 10/225,886 October 6,953,450 ISSUED			NEW		07/203,926		4,976,590	ISSUED
TRATES 00022 00022	022-PTA UT METHOD F	L ADMINISTRAT OR	TION OF IV LI	QUID MEDIC	'ATION AND IV	FLUSH SOLUTION	vs, appara:	rus and
			NEW		10/225,886	· ·	6,953,450	SSUED

METHOD AND SYSTEM FOR LABELING SYRINGE BODIES

UNITED

RE-

December

October

6,957,522

JTATES

EXAMINED

3, 2003

25, 2005

SYRINGE DOSE IDENTIFICATION SYSTEM

UNITED STATES NEW

October 8.

1999

October 8,

6,338,200

1999

ADJUSTABLY CONTROLLABLE ACCURACY-ENHANCING PUMP ARRANGEMENT AND METHOD

UNITED STATES

Allowed to expire: failed June 8, 1988

June 18, 1991

5,024,347

to pay

RE-

maintenance

fees

August 31,

1994

EXAMINED

SYRINGE DRIVER/SYRINGE/TUBE CONNECTING SET FLUID DELIVERY ARRANGEMENT; AND TUBE CONNECTING SETS THEREFORE

UNITED STATES

NEW

June 30,

September

4,863,429

1987 5, 1989

SYRINGE-TYPE LIQUID CONTAINER DISPENSER ADAPTER

UNITED STATES

NEW

March 14,

March 2, 1982

4,317,448

1980

UNITED STATES

NEW

June 19, 1980

December 1, 1981

4,303,071

PATIENT CONTROLLED INFUSION APPARATUS AND METHOD

UNITED STATES

NEW

November

August 4,

5,135,491

2, 1990 1992

SYRINGE HOLDER/DRIVER AND SYRINGE ARRANGEMENT AND SYRINGE/HOLDER DRIVER THEREFORE

UNITED STATES

NEW

June 30. 1987

July 5 ,1988

4,755,172

- 9 -

#1171798 v2

SCHEDULE B

United States Patent Applications

COUNTRY	REFERENCE #	Е ТҮРЕ	DATE FILED	SERIAL#	DATE ISSUED	PATENT	STATUS
003.01.02.0	1-PTA UTL CO	N HANDLING	SYRINGE	S, METHOD FOR			
UNITED STATES	50012-00042	CON					PROPOSED
UNITED STATES	50012-00053	RE- EXAMINED					PROPOSED
UNITED STATES	50012-00033	CON	June 9, 2004	10/864,610			PUBLISHED
021-PTA UT	'L STERILE DO	OCKING APP	ARATUS AI	ND METHOD			
NITED TATES	50012- 00021	NEW	August 22, 2002	10/226,183			PUBLISHED
022-PTA UT APPARATU	L ADMINISTR S AND METHO	ATION OF IV DD FOR	LIQUID M	EDICATION AND	IV FLUSH SO	LUTIONS,	
UNITED STATES	50012- 00043	DIVISIONAL	July 1, 2005	11/173,506		?	PUBLISHED
024-PTA UTI	L IMPROVED I	PROTECTIVE	CAP AND	CAPPING METHO	D FOR MEDI	CAL MALI	E LUER
UNITED STATES	50012- 00024	NEW	August 22, 2002	10/226,599		I	PUBLISHED
034-PTA UTI	. SWABABLE I	FLUID CONNI	ECTORS AI	ND FLUID CONNE	CTOR PAIRS		
UNITED STATES	50012- 00034	NEW	January 14, 2005	I 1/036,644		P	ENDING

- 10 -

040.01-PTA UTL CIP STERILE DOCKING APPARATUS AND METHOD

UNITED 50012-CIP PROPOSED **STATES** 00052 UNITED 50012-NEW May 10, 11/125,774 PENDING STATES 00040 2005 041-PTA UTL ADMINISTRATION OF IV LIQUID MEDICATION AND IV FLUSH SOLUTIONS, APPARATUS, METHOD AND SYSTEM FOR UNITED 50012-**NEW** October 11/242,618 PENDING STATES 00041 3, 2005 045-PTA PRO IMPROVED AUTOMATED MEDICAL LIQUID FILLING SYSTEM AND METHOD UNITED 50012-NEW December 60/742,114 PENDING STATES 00045 2,2005. Foreign Patent Applications COUNTRY REFERENCE TYPE DATE SERIAL# DATE PATENT **STATUS** # FILED ISSUED 003.01.02.01-PTA UTL CON HANDLING SYRINGES, METHOD FOR EUROPEAN 50012-00025 **DCA** August 01970534.2 **PUBLISHED** PATENT 10, 2001 021-PTA UTL STERILE DOCKING APPARATUS AND METHOD EUROPEAN 50012~ CEO August 03019090.4 PUBLISHED PATENT 00028 22, 2003 022-PTA UTL ADMINISTRATION OF IV LIQUID MEDICATION AND IV FLUSH SOLUTIONS, APPARATUS AND METHOD FOR

EUROPEAN 50012- CFO Avgust 02010001.2

EUROPEAN 50012-PATENT 00029

CEQ

August 22, 2003

03019091.2

PUBLISHED

034-PTA UTL SWABABLE FLUID CONNECTORS AND FLUID CONNECTOR PAIRS

-11-

WIPO

50012-00051 CEQ

January 12, 2006

PCT/US2006/00137

PENDING

- 12 ~

SCHEDULE C

United States Trademarks

Name	Mark Drawing Code	Status	Registration Number	Serial Number	Notes
Exacta-Med®	Standard Character Mark	Cancelled	1302479	73450421	Cancelled as of February 26, 1991. Resent application in June 2005 to renew registration.
MicroFuse®	Typed Drawing	Registered	2302872	75485472	Sent Declaration 8 and 15 to maintain registration in October 2005.
MicroFuse®	Design Plus Words, Letters, and/or Numbers	Registered	2386181	75485471	Sent Declaration 8 and 15 to maintain registration in October 2005.
Baxa	Typed Drawing	Cancelled	1388189	73366067	Cancelled as of November 4, 1992. Resent application in June 2005 to renew registration.

State Trademarks

	Exects Min	-	_		
	Exacta-Mix	Registered	0638994	CA111083200	Registration
J		-	}	1	1 TOPIOGRAPION
Ì		,		ļ	date: May 3,
į					2005.

- 13 - PA

Foreign Trademarks

í	7 . 7 . 7					
	CytoSafe® (Registered in Europe)	Typed Drawing	Registered	N/A	78261966	CytoSafe is
		Diawing]			also
j		i		ļ		registered by
				ļ		an Australian
ľ						vial
Ł			<u> </u>			producer.

- 14 -

#1171798 v2

SCHEDULE D

United States Trademark Applications

Name	Mark Drawing Code	Status	Registration Number	Serial Number	Notes
CathCare	Design Plus Words, Letters and/or Numbers; Standard Character Mark	Pending	N/A	N/A	Sent application in August 2005.
PadLock	Typed Drawing	Pending	N/A	N/A	Sent application in August 2005.
P2	Words, Letters, Numbers in Stylized Form	Pending		78884693	Sent application in May 2006.
P2	Standard Character Mark	Pending		78844590	Sent application in March 2006.
P2 Technology	Standard Character Mark	Pending		78844650	Sent application in March 2006.
РША	Standard Character Mark	Pending		78884693	Sent application in December 2005.

- 15 -

SCHEDULE E

Licenses

- 1. Agreement with Gerry Tighe, dated August 9, 2001, regarding Multi-Dose IV Flush Product. This agreement is exclusive, assignable, revocable upon certain conditions and for a term.
- 2. Agreement with Rod Okamoto and Tom Diamantidis and Nutrishare, dated May 29, 1999. This license is non-exclusive, revocable upon the occurrence of certain conditions, assignable and for a term.
- 3. Microsoft Select 6 Standard Enrollment Acceptance, Business Agreement, Select Agreement dated November 18, 2005, by and between the Company and Microsoft Licensing, GP. This license is non-exclusive, assignable, revocable upon breach, and remains in effect until terminated.
- Microsoft Select Agreement, dated February 23, 2006, by and between the Company and Microsoft Licensing, GP. This license is assignable, revocable upon breach, non-exclusive and for a tenn.
- 5. Mircrosoft OEM Customer License Agreement for Embedded Systems, dated October 13, 2005, by and between the Company and Microsoft Licensing, GP. This license is non-exclusive, nonassignable, revocable upon breach and other conditions and for a term.
- 6. Microsoft OEM Customer License Agreement for Use of Third Party Integrator, dated October 13, 2005, by and between the Company and Microsoft Licensing, GP. This license is non-exclusive, non-assignable, revocable upon breach and other conditions and for a term.
- 7. Intersourcing Service Model Agreement/Supplement to Ultimate Software Group, Inc. Software License and Support Maintenance Agreement dated April 4, 2001, dated on or about September 28, 2004, by and between the Company and the Ultimate Software Group. Also subject to the terms of the Purchase Agreement, dated April 4, 2001, by and between the Company and The Dovetail Group. This license is revocable upon termination and is assignable. Part of this license is for a term and the other part continues in effect until termination.
- 8. Services Agreement, dated April 30, 2002, by and between the Company and Revexion, LLC. The license is non-exclusive, non-assignable and non-transferable.
- 9. Distribution Agreement, dated October 30, 2002, by and between the Company and Carmel Pharma. This license is non-assignable, exclusive, revocable upon default by the Company and for a term (renews automatically).
- 10. Supplier User Agreement, dated December 1, 2005, by and between the Company and Global Healthcare Exchange. This license is non-exclusive, non-assignable, and for a term.
- 11. Consolidated Agreement, dated February 4, 2002, by and between the Company and Bridgelogix. This license is non-exclusive and non-transferable.

- 16 -

PATENT REEL: 018535 FRAME: 0357

RECORDED: 11/20/2006